Low

MS.S. Intended for piblication and books, etc.. intended fer review should be senlt to Professor J. McKeen Cattell, Garrisonon-Hludson, N. Y, THE CHARACTERIZATION AND CLASSIFICATION OF BACTERIAL TYPES' THE vast majority of students of microbial life are preoccupied with immediately practical problems, and most of them have been trained for their work from the standpoint of some practical art, medicine, veterinary science, sanitary engineering or agriculture, rather than from the more general and fundamental standpoint of the biologist. The Society of American Bacteriologists was founded as a protest against such necessary but dangerous specialization, to bring together workers in all fields for a consideration of their problems in the light of the underlying, unifying principles of bacteriology as a member of the group of the biologic sciences. It is this ideal which distinguishes our society from any other organization in America which deals with microbic life and its effects. It is of course fruitless to attempt to draw any sharp distinction between pure and applied science, and it would be a great pity if, as we gather year by year, we should fail to discuss together many of the more special problems of techn'ique with which we are concerned. In particular it is well that we should exercise the widest hospitality toward those branches of our science, such as dairy bacteriology and soil bacteriology which have no technical societies at their disposal, such as are available for the specialists in medical and sanitary lines. We should be untrue to our highest mission however, if we failed at the same time to emphasize those phases of our work in which this society of all others

[1]  B. Whipp,et al.  The role of nitrogen oxides in human adaptation to hypoxia , 2011, Scientific reports.

[2]  M. Feelisch The use of nitric oxide donors in pharmacological studies , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  S. Rice,et al.  Cephalosporin-3'-diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms. , 2012, Angewandte Chemie.

[4]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[5]  I. Chopra,et al.  Increased mutability of Pseudomonas aeruginosa in biofilms. , 2008, The Journal of antimicrobial chemotherapy.

[6]  T. Scheike,et al.  Polymorphonuclear Leukocytes Restrict Growth of Pseudomonas aeruginosa in the Lungs of Cystic Fibrosis Patients , 2014, Infection and Immunity.

[7]  P. Nielsen,et al.  True Microbiota Involved in Chronic Lung Infection of Cystic Fibrosis Patients Found by Culturing and 16S rRNA Gene Analysis , 2011, Journal of Clinical Microbiology.

[8]  Matthew R. Parsek,et al.  Pseudomonas aeruginosa Rugose Small-Colony Variants Have Adaptations That Likely Promote Persistence in the Cystic Fibrosis Lung , 2009, Journal of bacteriology.

[9]  Jeremy S. Webb,et al.  Nitric oxide‐mediated dispersal in single‐ and multi‐species biofilms of clinically and industrially relevant microorganisms , 2009, Microbial biotechnology.

[10]  D. Laskin,et al.  The toxicology of inhaled nitric oxide. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  N. Høiby,et al.  Eradication of early Pseudomonas aeruginosa infection. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  Xueji Zhang,et al.  Novel Calibration Method for Nitric Oxide Microsensors by Stoichiometrical Generation of Nitric Oxide from SNAP , 2000 .

[13]  J. Heesemann,et al.  Specific and Rapid Detection by Fluorescent In Situ Hybridization of Bacteria in Clinical Samples Obtained from Cystic Fibrosis Patients , 2000, Journal of Clinical Microbiology.

[14]  Philip S. Stewart,et al.  Contributions of Antibiotic Penetration, Oxygen Limitation, and Low Metabolic Activity to Tolerance of Pseudomonas aeruginosa Biofilms to Ciprofloxacin and Tobramycin , 2003, Antimicrobial Agents and Chemotherapy.

[15]  P. Williams,et al.  Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. , 2007, Microbiology.

[16]  Thomas Bjarnsholt,et al.  Towards diagnostic guidelines for biofilm-associated infections. , 2012, FEMS immunology and medical microbiology.

[17]  B. Ersbøll,et al.  Quantification of biofilm structures by the novel computer program COMSTAT. , 2000, Microbiology.

[18]  D. Hassett,et al.  Involvement of Nitric Oxide in Biofilm Dispersal of Pseudomonas aeruginosa , 2006, Journal of bacteriology.

[19]  Chris C. Miller,et al.  A phase I clinical study of inhaled nitric oxide in healthy adults. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[20]  Zbigniew Lewandowski,et al.  Effects of biofilm structures on oxygen distribution and mass transport , 1994, Biotechnology and bioengineering.

[21]  R. Amann,et al.  Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations , 1990, Applied and environmental microbiology.

[22]  D. Hassett,et al.  Nitric Oxide Signaling in Pseudomonas aeruginosa Biofilms Mediates Phosphodiesterase Activity, Decreased Cyclic Di-GMP Levels, and Enhanced Dispersal , 2009, Journal of bacteriology.

[23]  Garth D Ehrlich,et al.  Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. , 2006, JAMA.

[24]  M. Givskov,et al.  The immune system vs. Pseudomonas aeruginosa biofilms. , 2010, FEMS immunology and medical microbiology.

[25]  Lucas Smith,et al.  Phenotypic Characterization of Clonal and Nonclonal Pseudomonas aeruginosa Strains Isolated from Lungs of Adults with Cystic Fibrosis , 2007, Journal of Clinical Microbiology.

[26]  B. Rubin,et al.  Nitric oxide metabolites in cystic fibrosis lung disease , 1998, Archives of disease in childhood.

[27]  N. Bryan,et al.  Cellular targets and mechanisms of nitros(yl)ation: An insight into their nature and kinetics in vivo , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Oliver,et al.  ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[30]  L. Hoffman,et al.  Reducing bias in bacterial community analysis of lower respiratory infections , 2012, The ISME Journal.

[31]  Samuel I. Miller,et al.  The bacterial second messenger c‐di‐GMP: mechanisms of signalling , 2011, Cellular microbiology.

[32]  S. Aaron,et al.  Single and Combination Antibiotic Susceptibilities of Planktonic, Adherent, and Biofilm-Grown Pseudomonas aeruginosa Isolates Cultured from Sputa of Adults with Cystic Fibrosis , 2002, Journal of Clinical Microbiology.

[33]  Li Zhang,et al.  The exopolysaccharide Psl-eDNA interaction enables the formation of a biofilm skeleton in Pseudomonas aeruginosa. , 2015, Environmental microbiology reports.

[34]  S. Kjelleberg,et al.  Microbial biofilm formation: a need to act , 2014, Journal of internal medicine.

[35]  N. Bryan,et al.  Bound NO in human red blood cells: fact or artifact? , 2004, Nitric oxide : biology and chemistry.

[36]  M. Kühl,et al.  Physiological levels of nitrate support anoxic growth by denitrification of Pseudomonas aeruginosa at growth rates reported in cystic fibrosis lungs and sputum , 2014, Front. Microbiol..

[37]  S. Aaron,et al.  Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis , 2004, European Respiratory Journal.

[38]  A. Gieseke,et al.  Fluorescence "in situ" hybridization for the detection of biofilm in the middle ear and upper respiratory tract mucosa. , 2009, Methods in molecular biology.

[39]  Michael J. MacCoss,et al.  Aminoglycoside antibiotics induce bacterial biofilm formation , 2005, Nature.

[40]  S. Collins,et al.  Role of Mutation in Pseudomonas aeruginosa Biofilm Development , 2009, PloS one.

[41]  L. Nordvall,et al.  Oral bacteria--the missing link to ambiguous findings of exhaled nitrogen oxides in cystic fibrosis. , 2009, Respiratory medicine.

[42]  C. K. van der Ent,et al.  Nitric oxide in cystic fibrosis. , 2005, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[43]  S. Lory,et al.  Pseudomonas aeruginosa regulates flagellin expression as part of a global response to airway fluid from cystic fibrosis patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Vanderkelen,et al.  Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, oprI and oprL , 1997, Journal of clinical microbiology.

[45]  A. Quittner,et al.  Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. , 2000, Journal of pediatric psychology.

[46]  T. Tolker-Nielsen,et al.  Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB‐oprM genes , 2008, Molecular microbiology.

[47]  J. Costerton,et al.  Pseudomonas aeruginosa biofilm as a diffusion barrier to piperacillin , 1992, Antimicrobial Agents and Chemotherapy.

[48]  B. McCollister,et al.  Nitric Oxide Protects Bacteria from Aminoglycosides by Blocking the Energy-Dependent Phases of Drug Uptake , 2011, Antimicrobial Agents and Chemotherapy.

[49]  M. Schoenfisch,et al.  Anti-biofilm efficacy of nitric oxide-releasing silica nanoparticles. , 2009, Biomaterials.

[50]  F. Ratjen,et al.  Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[51]  H. Ceri,et al.  The Calgary Biofilm Device: New Technology for Rapid Determination of Antibiotic Susceptibilities of Bacterial Biofilms , 1999, Journal of Clinical Microbiology.

[52]  L. Hoffman,et al.  Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience , 2012, Thorax.

[53]  W. Zapol,et al.  Brief Periods of Nitric Oxide Inhalation Protect against Myocardial Ischemia–Reperfusion Injury , 2008, Anesthesiology.

[54]  M. Schoenfisch,et al.  Bactericidal efficacy of nitric oxide-releasing silica nanoparticles. , 2008, ACS nano.

[55]  S. Molin,et al.  The clinical impact of bacterial biofilms , 2011, International Journal of Oral Science.

[56]  A. Denicola,et al.  Acceleration of nitric oxide autoxidation and nitrosation by membranes , 2007, IUBMB life.

[57]  Chris C. Miller,et al.  Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. , 2009, Nitric oxide : biology and chemistry.

[58]  Pradeep K. Singh,et al.  Cystic Fibrosis Sputum Supports Growth and Cues Key Aspects of Pseudomonas aeruginosa Physiology , 2005, Journal of bacteriology.

[59]  Chris C. Miller,et al.  Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study , 2016, Infection.

[60]  Diane McDougald,et al.  Should we stay or should we go: mechanisms and ecological consequences for biofilm dispersal , 2011, Nature Reviews Microbiology.

[61]  A. Prince Biofilms, antimicrobial resistance, and airway infection. , 2002, The New England journal of medicine.

[62]  Gerald B. Pier,et al.  Lung Infections Associated with Cystic Fibrosis , 2002, Clinical Microbiology Reviews.

[63]  T. McMahon,et al.  Inhaled nitric oxide therapy increases blood nitrite, nitrate, and s-nitrosohemoglobin concentrations in infants with pulmonary hypertension. , 2012, The Journal of pediatrics.